The Motley Fool
27 Sept 2026, 13:16 UTC · 1h ago
Verdict
Headline takes no side. We score MDT +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 66% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Medtronic increased its fiscal 2027 full-year organic revenue growth forecast to 7.25% to 7.75% from a previous range of 6.75% to 7.25%.
Priced inanalysis of Q1 report from Sept 1
So whatThe raised guidance increases the floor for revenue expectations for the remainder of FY2027.
More positive than 79% of claims this week
Medtronic raised the lower end of its full-year non-GAAP diluted EPS guidance from $5.90 to $5.94.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of Q1 report from Sept 1
So whatA 4-cent increase in the EPS floor suggests improving operational efficiency or cost management through FY2027.
More positive than 66% of claims this week
Medtronic's dividend payout ratio has dropped to approximately 59%.
Priced inanalysis of Q1 results reported earlier
So whatThe gap between the current 59% ratio and a typical 75% ceiling provides headroom for dividend hikes beyond the recent 1.4% increase.
More positive than 53% of claims this week
The neuroscience unit is experiencing slower growth due to pricing pressure and competition from Globus Medical and Stryker.
Priced inanalysis of Q1 results reported earlier
So whatPricing pressure in this segment may cap overall margin expansion despite 9.3% growth.
More negative than 69% of claims this week
Which stocks this story touches
More positive than 66% of ticker scores this week
Strong fiscal 2027 Q1 results and raised guidance, though offset by long-term stock struggles and spinoff expenses.
More positive than 61% of ticker scores this week
Identified as the industry leader that Medtronic is spending heavily to compete against.
More positive than 55% of ticker scores this week
Cited as a competitor creating pricing pressure and slowing growth for Medtronic's neuroscience unit.
More positive than 55% of ticker scores this week
Cited as a competitor creating pricing pressure and slowing growth for Medtronic's neuroscience unit.
More negative than 64% of ticker scores this week
Mentioned as a spun-off business associated with ongoing expenses for the parent company.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
3h ago
More positive than 75% of relationship scores this week
[mutual] Medtronic's Hugo RAS robotic surgery business competes with industry leader Intuitive Surgical.
More positive than 56% of relationship scores this week
[mutual] Stryker is a rival to Medtronic's neuroscience unit.
More positive than 56% of relationship scores this week
[mutual] Globus Medical is a rival to Medtronic's neuroscience unit.
—
MDT hasn't traded since this ran. Last close $88.64 (Sep 25); the reaction starts at the next open.
MDT chart →
